Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2004British Journal of HaematologyOpen Access

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

Sundar Jagannath
Sundar JagannathNorthwestern University
Bart Barlogie
Bart BarlogieUniversity of Arkansas at Little RockJBJames R. BerensonOncotherapeutics (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jagannath et al. (2004) studied this question.

synapsesocial.com/papers/6a0f57d85725bbd5cc5faebfhttps://doi.org/10.1111/j.1365-2141.2004.05188.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How Proteolysis Drives the Cell Cycle1996 · 1,287 citations
  2. 2The Treatment of Multiple Myeloma1994 · 406 citations
  3. 3CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION1998 · 1,527 citations